285 Psoriasis resolution in challenging body areas with ixekizumab: Response trajectories by patient profile clusters over time

Abstract

To identify patients that benefit most from ixekizumab (IXE), unsupervised machine learning applied to Psoriasis Area and Severity Index (PASI) improvement was used to define IXE-response clusters in patients with psoriasis. Using these identified clusters based on PASI, responses in challenging body areas (CBA) as well as in Static Physicians Global Assessment (sPGA) were assessed through 52 weeks. These analyses included patients treated with on-label doses of IXE pooled from two Phase 3 clinical trials, UNCOVER-31 and IXORA-S2 .Response trajectories over 52 weeks were summarized for sPGA(0,1)/sPGA(0); CBA areas of Nail Psoriasis Severity Index 0 [NAPSI(0)], Psoriasis Scalp Severity Index 0 [PSSI(0)], and Palmoplantar Psoriasis Area and Severity Index 100 [PPASI(100)].